Mahzi Therapeutics
mahzi.com
Biologics & Biosimilars
Health Care
Rare Disease Therapeutics
As featured in
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$52.6M
1 round on record
Latest round
$52.6M
Venture round · Oct 2021 · 5 yr ago
Team
51-200
employees, estimated range
Backers
2
HBM Healthcare Investments, HealthCap
The money's age
Long since its last round
60 months since the last round · not hiring
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jul 8, 2024
Board appointment Stephen Farr, Director · SEC Form D
Oct 7, 2021
Raised a round Venture round $52.6M · SEC Form D
2020
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Oct 2021 | $52.6M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Mahzi Therapeutics, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Yael WeissExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
HBM Healthcare Investments 
HealthCap Investors in similar startupsfunds that back the companies most like this one
backs Mendra window
backs Sidewinder Therapeutics
Similar startupsby what they do, their industry and backers
Sidewinder Therapeutics is pioneering the next generation of large molecule precision therapeutics. We aim to deliver new life-saving…
Mendra is a venture-backed rare-disease biopharma accelerating the development and commercialization of de-risked breakthrough therapies.
Nuance Pharma are an innovation focused biopharmaceutical company, with both late-stage clinical pipeline and commercial stage asset…
Theradaptive aims to redefine the regenerative medicine field by delivering therapeutics to any location in the body with precision.
Celestial Therapeutics is developing novel therapies based on innovative and groundbreaking science to treat, prevent and cure infectious…
ReCode is the first genetic medicines platform to enable highly targeted delivery to organs, tissues and cells beyond the liver. Our…
Overview
Mahzi aims to unite patient and family groups, academic researchers, other industry members, and our internal team of experts to develop therapies for patients with under-diagnosed and under-served rare genetic neurodevelopmental disorders.
News
Mahzi Therapeutics Announces FDA Rare Pediatric Disease Designation for MZ-1866 Investigational Therapy for Pitt Hopkins Syndrome
Read more
Report
Mahzi Therapeutics Announces First Patient Dosed in Phase 1/2 UNITE Study of MZ-1866 for Pitt Hopkins Syndrome
Mahzi Therapeutics Inc., a clinical-stage biotechnology company developing precision therapies for neurogenetic disorders, today announced that the first patient has been dosed in its Phase 1/2 UNITE study evaluating MZ-1866, an investigational gene thera
Read more
Report
People
Yael Weiss
Executive Officer, Director
Shalini Sharp
Director
Camille Samuels
Director
Marten Steen
Director
Stephen Farr
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
South San Francisco
United States
HQ
50-200 est. staff
Financials
Total raised
$52.6M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2021 | $52.6M | Details |